
Ran Kornowski Facc, Fesc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6084599/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Clinical SYNTAX score predicts survival better than the SYNTAX score in coronary revascularization. Journal of Thoracic and Cardiovascular Surgery, 2024, 167, 164-173.e4.	0.8	2
2	Patient-reported outcome measures in cardiovascular disease. European Heart Journal Quality of Care & Clinical Outcomes, 2023, 9, 119-127.	4.0	14
3	The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2022, 36, 85-92.	2.6	10
4	Impact of sex on outcomes of bifurcation lesion percutaneous coronary intervention: results from a single-centre prospective registry. Coronary Artery Disease, 2022, 33, 31-36.	0.7	4
5	Trends in ST-elevation myocardial infarction. Coronary Artery Disease, 2022, 33, 1-8.	0.7	3
6	The clinical value of the endocarditis team: insights from before and after guidelines implementation strategy. Infection, 2022, 50, 57-64.	4.7	10
7	Natural History and Prognosis of Patients with Unrepaired Tricuspid Regurgitation Undergoing Implantation of Left Ventricular Assist Device. ASAIO Journal, 2022, 68, 508-515.	1.6	5
8	Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. European Heart Journal Cardiovascular Imaging, 2022, 23, 1075-1082.	1.2	29
9	Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry. International Journal of Cardiology, 2022, 349, 31-38.	1.7	4
10	Comparison of Simultaneous Transthoracic Versus Transesophageal Echocardiography for Assessment of Aortic Stenosis. American Journal of Cardiology, 2022, 163, 77-84.	1.6	2
11	Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2022, 36, 467-473.	2.6	0
12	Diffused coronary involvement in Takayasu arteritis with concomitant malignancy. Clinical Rheumatology, 2022, 41, 921-928.	2.2	2
13	Sixâ€months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist deviceâ€supported patients. ESC Heart Failure, 2022, , .	3.1	4
14	The V-LAP System for Remote Left Atrial Pressure Monitoring of Patients With Heart Failure. Journal of Cardiac Failure, 2022, 28, 963-972.	1.7	20
15	The Association between Low Levels of Low Density Lipoprotein Cholesterol and Intracerebral Hemorrhage: Cause for Concern?. Journal of Clinical Medicine, 2022, 11, 536.	2.4	7
16	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	2.9	6
17	The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. Journal of Clinical Medicine, 2022, 11, 865.	2.4	8
18	Management and Outcome of FailedÂPercutaneous Edge-to-Edge MitralÂValveÂPlasty. JACC: Cardiovascular Interventions, 2022, 15, 411-422.	2.9	7

#	Article	IF	CITATIONS
19	Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease. Nature Medicine, 2022, 28, 295-302.	30.7	74
20	Chronic Renal Failure and Cardiovascular Disease: A Comprehensive Appraisal. Journal of Clinical Medicine, 2022, 11, 1335.	2.4	7
21	Microbiome and metabolome features of the cardiometabolic disease spectrum. Nature Medicine, 2022, 28, 303-314.	30.7	102
22	A Case Series of Myocarditis Following Third (Booster) Dose of COVID-19 Vaccination: Magnetic Resonance Imaging Study. Frontiers in Cardiovascular Medicine, 2022, 9, 839090.	2.4	14
23	Impact of Valve Size on Paravalvular Leak and Valve Hemodynamics in Patients With Borderline Size Aortic Valve Annulus. Frontiers in Cardiovascular Medicine, 2022, 9, 847259.	2.4	2
24	Outcomes in Valve-in-Valve Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 172, 81-89.	1.6	11
25	Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination. Open Heart, 2022, 9, e001957.	2.3	19
26	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	3.0	5
27	Mechanical vs Bioprosthetic Aortic Valve Replacement in Patients Younger Than 70 Years of Age: A Hazard Ratio Meta-analysis. Canadian Journal of Cardiology, 2022, 38, 355-364.	1.7	6
28	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	3.2	5
29	Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	3
30	Management and outcomes over time of acute coronary syndrome patients at particularly high cardiovascular risk : the ACSIS registry-based retrospective study. BMJ Open, 2022, 12, e060953.	1.9	1
31	Five-Year Outcomes of Patients With Mitral Structural Valve Deterioration Treated With Transcatheter Valve in Valve Implantation – A Single Center Prospective Registry. Frontiers in Cardiovascular Medicine, 2022, 9, 883242.	2.4	3
32	Tricuspid Structural Valve Deterioration Treated with a Transcatheter Valve-in-Valve Implantation: A Single-Center Prospective Registry. Journal of Clinical Medicine, 2022, 11, 2667.	2.4	2
33	Association of socioeconomic status measures with physical activity and subsequent frailty in older adults. BMC Geriatrics, 2022, 22, 439.	2.7	2
34	Local Anesthesia versus Conscious Sedation among Patients Undergoing Transcatheter Aortic Valve Implantation—A Propensity Score Analysis. Journal of Clinical Medicine, 2022, 11, 3134.	2.4	0
35	Cardiac CT for intra-cardiac thrombus detection in embolic stroke of undetermined source (ESUS). European Stroke Journal, 2022, 7, 212-220.	5.5	6
36	Clinical Predictors for Procedural Stroke and Implications for Embolic Protection Devices during TAVR: Results from the Multicenter Transcatheter Aortic Valve Replacement In-Hospital Stroke (TASK) Study. Journal of Personalized Medicine, 2022, 12, 1056.	2.5	1

#	Article	IF	CITATIONS
37	Self-Reported Mental and Physical Measures in Adult Fontan Patients. Journal of Clinical Medicine, 2022, 11, 3969.	2.4	1
38	Short membranous septum length in bicuspid aortic valve stenosis increases the risk of conduction disturbances. Journal of Cardiovascular Computed Tomography, 2021, 15, 339-347.	1.3	24
39	Transcatheter Mitral Valve Replacement After Surgical Repair or Replacement. Circulation, 2021, 143, 104-116.	1.6	94
40	Temporal trends of acute kidney injury in patients undergoing percutaneous coronary intervention over a span of 12Âyears. International Journal of Cardiology, 2021, 326, 44-48.	1.7	7
41	Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry. International Journal of Cardiology, 2021, 325, 109-114.	1.7	19
42	Distribution of Câ€arm projections in native and bioprosthetic aortic valves cusps: Implication for BASILICA procedures. Catheterization and Cardiovascular Interventions, 2021, 97, E580-E587.	1.7	2
43	Report from a large and comprehensive single-center Women's Health Cardiology Clinic. Women's Health, 2021, 17, 174550652110137.	1.5	1
44	Temporary Trends in Fever following Transcatheter Aortic Valve Implantation. Cardiology, 2021, 146, 359-367.	1.4	2
45	A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with optimal medical therapy in stable obstructive coronary artery disease. Coronary Artery Disease, 2021, 32, 618-624.	0.7	3
46	Outcome of patients with prior coronary bypass surgery admitted with an acute coronary syndrome. Heart, 2021, 107, heartjnl-2020-318047.	2.9	1
47	Timing of Nonculprit Percutaneous Coronary Intervention after ST-Elevation Myocardial Infarction. Cardiology, 2021, 146, 556-565.	1.4	0
48	Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis. Clinical Research in Cardiology, 2021, 110, 667-675.	3.3	8
49	Hospital admissions for acute coronary syndrome during the first wave of COVID-19 pandemic in Israel. Coronary Artery Disease, 2021, Publish Ahead of Print, 658-660.	0.7	3
50	Complex Catheter-Based Structural HeartÂReconstruction in a Patient WithÂTricuspid Atresia and BjörkÂPalliative Conduit. JACC: Case Reports, 2021, 3, 212-216.	0.6	2
51	Long Term Outcomes of Patients Treated With Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 141, 72-78.	1.6	4
52	Healthâ€related quality of life in left ventricular assist deviceâ€supported patients. ESC Heart Failure, 2021, 8, 2036-2044.	3.1	6
53	Prognostic implication of right ventricular dysfunction and tricuspid regurgitation following transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2021, 98, E758-E767.	1.7	6
54	Temporal trends in short and long-term outcomes after percutaneous coronary interventions among cancer patients. Heart and Vessels, 2021, 36, 1283-1289.	1.2	6

#	Article	IF	CITATIONS
55	Elevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome. Mediators of Inflammation, 2021, 2021, 1-9.	3.0	3
56	The Clinical Challenge of ST-Segment Elevation Myocardial Infarction and COVID-19. Journal of the American College of Cardiology, 2021, 77, 2004-2006.	2.8	6
57	Reducing Acute Kidney Injury After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2021, 14, e010718.	3.9	4
58	Transcatheter Aortic Valve Implantation for Failed Surgical Aortic Bioprostheses Using a Self-Expanding Device (from the Prospective VIVA Post Market Study). American Journal of Cardiology, 2021, 144, 118-124.	1.6	0
59	Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. Cardiovascular Diabetology, 2021, 20, 90.	6.8	30
60	Epicardial fat and the risk of atrial tachy-arrhythmia recurrence post pulmonary vein isolation: a computed tomography study. International Journal of Cardiovascular Imaging, 2021, 37, 2785-2790.	1.5	8
61	Same day discharge: How much less is more for TAVR patients?. Catheterization and Cardiovascular Interventions, 2021, 97, 948-949.	1.7	1
62	The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin Platelet Reactivity. Cardiovascular Drugs and Therapy, 2021, , 1.	2.6	1
63	Elderly Suffering from ST-Segment Elevation Myocardial Infarction—Results from a Database Analysis from Two Mediterranean Medical Centers. Journal of Clinical Medicine, 2021, 10, 2435.	2.4	3
64	Percutaneous mechanical circulatory support from the collaborative multicenter Mechanical Unusual Support in <scp>TAVI</scp> (<scp>MUST</scp>) Registry. Catheterization and Cardiovascular Interventions, 2021, 98, E862-E869.	1.7	9
65	Clinical significance of myocardial involvement in acute idiopathic pericarditis. Cardiology Journal, 2021, 28, 411-415.	1.2	3
66	Immunogenicity of the <scp>BNT162b2 mRNA</scp> vaccine in heart transplant <scp>recipients–Âa</scp> prospective cohort study. European Journal of Heart Failure, 2021, 23, 1555-1559.	7.1	71
67	Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2263-2273.	2.8	19
68	Generation of vascular chimerism within donor organs. Scientific Reports, 2021, 11, 13437.	3.3	10
69	Effect of Transcatheter Aortic Valve Replacement on Concomitant Mitral Regurgitation andÂltsÂlmpact on Mortality. JACC: Cardiovascular Interventions, 2021, 14, 1181-1192.	2.9	31
70	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC: Cardiovascular Interventions, 2021, 14, 1434-1446.	2.9	13
71	Incidence, Causes, and Outcomes Associated With Urgent Implantation of a Supplementary Valve During Transcatheter Aortic Valve Replacement. JAMA Cardiology, 2021, 6, 936.	6.1	7
72	Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis. PLoS ONE, 2021, 16, e0255487.	2.5	8

#	Article	IF	CITATIONS
73	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	2.2	18
74	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	2.8	111
75	First-in-Human Percutaneous Transcatheter Tricuspid Valve Replacement With a Novel Valve. JACC: Case Reports, 2021, 3, 1281-1286.	0.6	7
76	Comparison of permanent pacemaker implantation rate after first and second generation of transcatheter aortic valve implantation–A retrospective cohort study. Catheterization and Cardiovascular Interventions, 2021, 98, E990-E999.	1.7	3
77	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation, 2021, 144, 1196-1211.	1.6	41
78	5 Year Outcomes of Patients With Aortic Structural Valve Deterioration Treated With Transcatheter Valve in Valve – A Single Center Prospective Registry. Frontiers in Cardiovascular Medicine, 2021, 8, 713341.	2.4	0
79	Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. Journal of Clinical Medicine, 2021, 10, 4005.	2.4	7
80	Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry). American Journal of Cardiology, 2021, 159, 87-93.	1.6	1
81	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1032.	6.1	27
82	The Effect of Tafamidis on Circulating Endothelial Progenitor Cells in Patients with Transthyretin Cardiac Amyloidosis. Cardiovascular Drugs and Therapy, 2021, , 1.	2.6	0
83	Management and outcome across the spectrum of highâ€risk patients with myocardial infarction according to the thrmobolysis in myocardial infarction (TIMI) riskâ€score for secondary prevention. Clinical Cardiology, 2021, 44, 1535-1542.	1.8	5
84	Increased Rate of New-onset Left Bundle Branch Block in Patients With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation (From a National Registry). American Journal of Cardiology, 2021, 156, 101-107.	1.6	3
85	The Definition of "Acute Kidney Injury―Following Percutaneous Coronary Intervention and Cardiovascular Outcomes. American Journal of Cardiology, 2021, 156, 39-43.	1.6	3
86	Temporal trends in the pre-procedural TIMI flow grade among patients with ST- segment elevation myocardial infarction – From the ACSIS registry. IJC Heart and Vasculature, 2021, 36, 100868.	1.1	2
87	Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiology, 2021, 146, 1-6.	1.4	0
88	Heart Team/Guidelines Discordance Is Associated With Increased Mortality: Data From a National Survey of Revascularization in Patients With Complex Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2021, 14, e009686.	3.9	6
89	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
90	Transcatheter Replacement of Transcatheter Versus Surgically Implanted AorticÂValveÂBioprostheses. Journal of the American College of Cardiology, 2021, 77, 1-14.	2.8	64

#	Article	IF	CITATIONS
91	Right Coronary Artery "Vessel Floating Sign―in a Patient With Primary CardiacÂLymphoma. JACC: Case Reports, 2021, 3, 1524-1526.	0.6	0
92	Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. New England Journal of Medicine, 2021, 385, 2132-2139.	27.0	473
93	Acute Kidney Injury Following Admission with Acute Coronary Syndrome: The Role of Diabetes Mellitus. Journal of Clinical Medicine, 2021, 10, 4931.	2.4	4
94	Coronary Artery Disease in Women: A Comprehensive Appraisal. Journal of Clinical Medicine, 2021, 10, 4664.	2.4	7
95	Temporal Trends in the Characteristics, Treatment, and Outcomes of Conservatively Managed Patients With Non-ST Elevation Acute Coronary Syndrome (from the ACSIS Registry 2000 to 2016). American Journal of Cardiology, 2021, 159, 52-58.	1.6	0
96	Worse outcomes of ACS patients without versus with traditional cardiovascular risk factors. Journal of Cardiology, 2021, , .	1.9	3
97	Temporal Trends and Outcome of Patients with Acute Coronary Syndrome and Prior Myocardial Infarction. Journal of Clinical Medicine, 2021, 10, 5580.	2.4	4
98	Severe aortic stenosis echocardiographic thresholds revisited. Echocardiography, 2021, 38, 2016-2024.	0.9	1
99	Left main coronary revascularization strategies in the COVID â€19 era. Catheterization and Cardiovascular Interventions, 2021, 98, 1262-1263.	1.7	1
100	90 Annular size and interaction with trans-catheter aortic valves for the treatment of severe bicuspid aortic valve stenosis: insights from the beat registry. European Heart Journal Supplements, 2021, 23, .	0.1	0
101	Comparison of longâ€term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimusâ€eluting stent or permanent polymer everolimusâ€eluting stent: 5â€year results of the CENTURY II randomized clinical trial. Catheterization and Cardiovascular Interventions, 2020, 95, 175-184.	1.7	8
102	Prognostic significance of the Medina classification in bifurcation lesion percutaneous coronary intervention with second-generation drug-eluting stents. Heart and Vessels, 2020, 35, 331-339.	1.2	11
103	Validation of the DAPT score in real-world patients undergoing coronary stent implantation. International Journal of Cardiology, 2020, 300, 99-105.	1.7	12
104	TAVI in bicuspid aortic valve stenosis. International Journal of Cardiology, 2020, 298, 83-84.	1.7	5
105	Changes over time in serum albumin levels predict outcomes following percutaneous coronary intervention. Journal of Cardiology, 2020, 75, 381-386.	1.9	9
106	Percutaneous nitinolâ€based vascular closure device for large bore arterial access hemostasis: Results of a prospective multicenter study. Catheterization and Cardiovascular Interventions, 2020, 96, 473-478.	1.7	5
107	Outcomes of primary percutaneous cardiac intervention for ST elevation myocardial infarction with a saphenous vein graft culprit. Catheterization and Cardiovascular Interventions, 2020, 96, E75-E83.	1.7	1
108	Impact of preprocedural left ventricle hypertrophy and geometrical patterns on mortality following TAVR. American Heart Journal, 2020, 220, 184-191.	2.7	12

#	Article	IF	CITATIONS
109	Relation of Hypoalbuminemia to Response to Aspirin in Patients With Stable Coronary Artery Disease. American Journal of Cardiology, 2020, 125, 303-308.	1.6	7
110	Meta-analysis of studies examining the external validity of the dual antiplatelet therapy score. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 285-291.	3.0	15
111	A risk score based on simple angiographic characteristics to aid in choosing the optimal revascularization strategy for patients with multivessel disease presenting with ST-elevation myocardial infarction. Coronary Artery Disease, 2020, 31, 597-605.	0.7	Ο
112	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
113	Safety and efficacy of the NovaCross microcatheter in facilitating crossing of chronic total occlusion coronary lesions: a multicenter, single-arm clinical trial. Coronary Artery Disease, 2020, 31, 573-577.	0.7	1
114	Natural History and Disease Progression of Early Cardiac Amyloidosis Evaluated by Echocardiography. American Journal of Cardiology, 2020, 133, 126-133.	1.6	13
115	The Scattering of Cold Nanorods Combined with Differential Uptake, Paving a New Detection Method for Macrophage Subtypes Using Flow Cytometery. Nano Letters, 2020, 20, 8360-8368.	9.1	15
116	Appraisal of urgent transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2020, 96, 196-197.	1.7	1
117	Leptin modulates gene expression in the heart and cardiomyocytes towards mitigating ischemia-induced damage. Experimental Cell Research, 2020, 397, 112373.	2.6	10
118	Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVR. JACC: Cardiovascular Interventions, 2020, 13, 2782-2791.	2.9	29
119	Management and Outcomes of Transvenous Pacing Leads in PatientsÂUndergoing Transcatheter Tricuspid Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2012-2020.	2.9	24
120	The Challenge of Percutaneous Coronary Interventions (PCIs) in Patients Presenting With Atrial Fibrillation in Conjunction With Myocardial Infarction. Cardiovascular Revascularization Medicine, 2020, 21, 855-856.	0.8	0
121	Bicuspid Aortic Valve Morphology andÂOutcomes After Transcatheter AorticÂValve Replacement. Journal of the American College of Cardiology, 2020, 76, 1018-1030.	2.8	143
122	Treating cardiogenic shock and cardiac arrest: The right place, the right time, the right equipment. Catheterization and Cardiovascular Interventions, 2020, 96, 556-557.	1.7	1
123	A rise in left atrial pressure detected by the Vâ€LAPâ"¢ system for patients with heart failure during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 4361-4366.	3.1	8
124	Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction. Journal of the American College of Cardiology, 2020, 75, 1882-1893.	2.8	140
125	Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?. Acta Haematologica, 2020, 143, 417-424.	1.4	92
126	Cardiac Care of Patients with Cardiac Amyloidosis. Acta Haematologica, 2020, 143, 343-351.	1.4	9

#	Article	IF	CITATIONS
127	Coronary ostial eccentricity in severe aortic stenosis: Guidance for BASILICA transcatheter leaflet laceration. Journal of Cardiovascular Computed Tomography, 2020, 14, 516-519.	1.3	14
128	Shifting Paradigms in CardiovascularÂTherapeutic Strategies During the COVID-19 Era. JACC: Cardiovascular Interventions, 2020, 13, 1949-1950.	2.9	3
129	Elevated galectin-3 in women with gestational diabetes mellitus, a new surrogate for cardiovascular disease in women. PLoS ONE, 2020, 15, e0234732.	2.5	12
130	Current Status of Cardiovascular Medicine in Israel. Circulation, 2020, 142, 17-19.	1.6	4
131	Prior Carpal Tunnel Syndrome and Early Concomitant Echocardiographic Findings Among Patients With Cardiac Amyloidosis. Journal of Cardiac Failure, 2020, 26, 909-916.	1.7	8
132	Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves. European Heart Journal, 2020, 41, 2731-2742.	2.2	97
133	Balloon Versus Self-Expandable Valve for the Treatment of Bicuspid Aortic Valve Stenosis. Circulation: Cardiovascular Interventions, 2020, 13, e008714.	3.9	62
134	Predicting the risk of late futile outcome after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2020, 96, E695-E702.	1.7	4
135	Temporal trends of patients with acute coronary syndrome and multi-vessel coronary artery disease - from the ACSIS registry. International Journal of Cardiology, 2020, 304, 8-13.	1.7	12
136	Non-Invasive Hemodynamic Whole-Body Bioimpedance Indices for the Early Detection of Cancer Treatment-Related Cardiotoxicity: A Retrospective Observational Study. Cardiology, 2020, 145, 350-355.	1.4	0
137	Coronary Protection to Prevent Coronary Obstruction During TAVR. JACC: Cardiovascular Interventions, 2020, 13, 739-747.	2.9	58
138	Temporal Trends of the Management and Outcome of Patients With Myocardial Infarction According to the Risk for Recurrent Cardiovascular Events. American Journal of Medicine, 2020, 133, 839-847.e2.	1.5	6
139	Diagnostic Performance of Angiogram-Derived FractionalÂFlowÂReserve. JACC: Cardiovascular Interventions, 2020, 13, 488-497.	2.9	33
140	Managing Combined Mitral and TricuspidÂRegurgitation. JACC: Cardiovascular Interventions, 2020, 13, 551-553.	2.9	0
141	Validation of cardiac damage classification and addition of albumin in a large cohort of patients undergoing transcatheter aortic valve replacement. International Journal of Cardiology, 2020, 304, 23-28.	1.7	10
142	Transcatheter aortic valve replacement with Lotus and Sapien 3 prosthetic valves: a systematic review and meta-analysis. Journal of Thoracic Disease, 2020, 12, 893-906.	1.4	7
143	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	2.8	60
144	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	2.8	122

#	Article	IF	CITATIONS
145	Extracorporeal membrane oxygenation therapy in the COVID-19 pandemic. Future Cardiology, 2020, 16, 543-546.	1.2	12
146	Long-term outcomes of percutaneous coronary intervention for unprotected left main coronary artery according to the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) score. Coronary Artery Disease, 2020, 31, 336-341.	0.7	1
147	Coronary Stenosis Physiology and Novel Technologies. Rambam Maimonides Medical Journal, 2020, 11, e0012.	1.0	0
148	Prediction of mortality in hospital survivors of STEMI: External validation of a novel acute myocardial infarction prognostic score. Cardiovascular Revascularization Medicine, 2019, 20, 96-100.	0.8	6
149	Hyperlipidemic mice as a model for a realâ€time in vivo detection of atherosclerosis by gold nanorodsâ€based diffusion reflection technique. Journal of Biophotonics, 2019, 12, e201800218.	2.3	4
150	Response by Fearon et al to Letter Regarding Article, "Accuracy of Fractional Flow Reserve Derived From Coronary Angiography― Circulation, 2019, 140, e96-e97.	1.6	1
151	The pros and cons of the Heart Team. Future Cardiology, 2019, 15, 255-258.	1.2	5
152	Echocardiographic Assessment of Aortic Stenosis under Sedation Underestimates Stenosis Severity. Journal of the American Society of Echocardiography, 2019, 32, 1051-1057.	2.8	8
153	Imaging of Aortic Valve Cusps Using Commissural Alignment. JACC: Cardiovascular Imaging, 2019, 12, 2262-2265.	5.3	5
154	Cancer and mortality in relation to traffic-related air pollution among coronary patients: Using an ensemble of exposure estimates to identify high-risk individuals. Environmental Research, 2019, 176, 108560.	7.5	14
155	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation, 2019, 140, 420-433.	1.6	263
156	Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease. Mayo Clinic Proceedings, 2019, 94, 1171-1179.	3.0	4
157	An 18-month comparison of clinical outcomes between continuous-flow left ventricular assist devices. European Journal of Cardio-thoracic Surgery, 2019, 56, 1054-1061.	1.4	12
158	Effect of Intramural Course of Coronary Arteries Assessed by Computed Tomography Angiography in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2019, 124, 1279-1285.	1.6	6
159	Temporal Trends in the Characteristics, Management and Outcomes of Patients With Acute Coronary Syndrome According to Their Killip Class. American Journal of Cardiology, 2019, 124, 1862-1868.	1.6	13
160	Transcatheter aortic valve replacement for oncology patients with severe symptomatic aortic stenosis: New hope for a complicated medical condition. Catheterization and Cardiovascular Interventions, 2019, 94, 446-447.	1.7	2
161	Long-Term Functional and Structural Durability of Bioprosthetic Valves Placed in the Aortic Valve Position via Percutaneous Rout in Israel. American Journal of Cardiology, 2019, 124, 1748-1756.	1.6	4
162	Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and CardiogenicÂShock. JACC: CardioOncology, 2019, 1, 141-144.	4.0	8

#	Article	IF	CITATIONS
163	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	2.8	71
164	Comparison of Outcomes in Patients With Acute Coronary Syndrome Presenting With Typical Versus Atypical Symptoms. American Journal of Cardiology, 2019, 124, 1851-1856.	1.6	10
165	Long-Term Outcomes After Mitral Valve Replacement and Tricuspid Annuloplasty in Rheumatic Patients. Annals of Thoracic Surgery, 2019, 107, 539-545.	1.3	15
166	International comparison of acute myocardial infarction care and outcomes using quality indicators. Heart, 2019, 105, 820-825.	2.9	17
167	lliofemoral artery lumen volume assessment with three dimensional multi-detector computed tomography and vascular complication risk in transfemoral transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2019, 13, 68-74.	1.3	6
168	Transfemoral TAVR in Nonagenarians. JACC: Cardiovascular Interventions, 2019, 12, 911-920.	2.9	27
169	TAVR for Failed Surgical AorticÂBioprostheses Using a Self-Expanding Device. JACC: Cardiovascular Interventions, 2019, 12, 923-932.	2.9	31
170	"No option―patients for coronary revascularization: the only thing that is constant is change. Journal of Thoracic Disease, 2019, 11, S300-S302.	1.4	0
171	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	3.9	71
172	Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction. European Heart Journal, 2019, 40, 1909-1919.	2.2	32
173	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e343-e348.	0.4	7
174	Transcatheter Aortic Valve Replacement Outcomes in Patients With Native vs Transplanted Kidneys: Data From an International Multicenter Registry. Canadian Journal of Cardiology, 2019, 35, 1114-1123.	1.7	12
175	Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease. PLoS ONE, 2019, 14, e0209661.	2.5	0
176	Complete heart block following TAVR: blocking the way forward?. Catheterization and Cardiovascular Interventions, 2019, 94, 781-782.	1.7	0
177	Characteristics and outcomes of patients with cancer presenting with acute myocardial infarction. Coronary Artery Disease, 2019, 30, 332-338.	0.7	9
178	Transcathether aortic valve implantation with the new repositionable self-expandable Medtronic Evolut R vs. CoreValve system. Journal of Cardiovascular Medicine, 2019, 20, 226-236.	1.5	9
179	Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. European Heart Journal, 2019, 40, 456-465.	2.2	100
180	Outcomes of Transcatheter Aortic Valve Implantation in Patients With Low Versus Intermediate to High Surgical Risk. American Journal of Cardiology, 2019, 123, 644-649.	1.6	9

#	Article	IF	CITATIONS
181	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. American Heart Journal, 2019, 209, 97-105.	2.7	53
182	Transcatheter Aortic Valve Replacement in Oncology Patients With Severe AorticÂStenosis. JACC: Cardiovascular Interventions, 2019, 12, 78-86.	2.9	53
183	Mid-Term Valve-Related Outcomes After Transcatheter Tricuspid Valve-in-Valve or Valve-in-Ring Replacement. Journal of the American College of Cardiology, 2019, 73, 148-157.	2.8	83
184	Bicuspid Aortic Valve Anatomy and Relationship With Devices: The BAVARD Multicenter Registry. Circulation: Cardiovascular Interventions, 2019, 12, e007107.	3.9	125
185	Dysfunctional endothelial progenitor cells in patients with Hodgkin's lymphoma in complete remission. Cancer Medicine, 2019, 8, 305-310.	2.8	3
186	The effect of periprocedural beta blocker withdrawal on arrhythmic risk following transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2019, 93, 1361-1366.	1.7	10
187	Efficacy and safety of new-generation transcatheter aortic valves: insights from the Israeli transcatheter aortic valve replacement registry. Clinical Research in Cardiology, 2019, 108, 430-437.	3.3	30
188	Temporal Trends in Gender-Related Differences and Outcomes in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the Israeli Transcatheter Aortic Valve Implantation) Tj ETQq0 0 0 r	gB 1. ¢Overl	oc b 010 Tf 50
189	Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. Circulation, 2019, 139, 477-484.	1.6	151
190	Meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at low surgical risk. EuroIntervention, 2019, 15, e1047-e1056.	3.2	22
191	Neuroprotective measures throughout the TAVI pathway. Minerva Cardioangiologica, 2019, 67, 39-56.	1.2	1
192	Reduced Number and Function of Endothelial Progenitor Cells in Patients with Beta Thalassemia Major. Blood, 2019, 134, 2247-2247.	1.4	0
193	Long-term Israeli Single-Center Experience with the Percutaneous MitraClip Procedure. Israel Medical Association Journal, 2019, 21, 308-313.	0.1	0
194	Prognostic and Diagnostic Significance of Serum High-Sensitivity C-Reactive Protein Level in Patients with Acute Idiopathic Pericarditis. Israel Medical Association Journal, 2019, 21, 747-751.	0.1	5
195	Transcatheter versus surgical aortic valve replacement in patients at low surgical risk: A metaâ€analysis of randomized trials and propensity score matched observational studies. Catheterization and Cardiovascular Interventions, 2018, 92, 408-416.	1.7	47
196	Impact of Pre-Existing Prosthesis-Patient Mismatch on Survival Following AorticÂValve-in-ValveÀProcedures. JACC: Cardiovascular Interventions, 2018, 11, 133-141.	2.9	91
197	Incidence, predictors and clinical outcomes of residual stenosis after aortic valve-in-valve. Heart, 2018, 104, 828-834.	2.9	64
198	Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation, 2018, 137, 388-399.	1.6	350

#	Article	IF	CITATIONS
100	Incidence and Prognosis of Pericarditis After ST-Elevation Myocardial Infarction (from the Acute) Tj ETQq1		
199	2018, 121, 690-694.	1.6	15
200	Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). European Heart Journal, 2018, 39, 676-684.	2.2	91
201	Impact of Coronary Artery Revascularization Completeness on Outcomes of Patients With Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e006000.	3.9	54
202	MitraClipâ€induced systolic anterior motion complicated by pericardial effusion: A case report. Catheterization and Cardiovascular Interventions, 2018, 91, 1371-1374.	1.7	1
203	Transcatheter aortic valve implantation in degenerative sutureless perceval aortic bioprosthesis. Catheterization and Cardiovascular Interventions, 2018, 91, 1000-1004.	1.7	15
204	Usefulness of the CHA 2 DS 2 -VASc Score to Predict Outcome in Patients Who Underwent Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2018, 121, 241-248.	1.6	18
205	Temporal trends in percutaneous coronary interventions thru the drug eluting stent era: Insights from 18,641 procedures performed over 12â€year period. Catheterization and Cardiovascular Interventions, 2018, 92, E262-E270.	1.7	26
206	Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids?. Journal of Cardiology, 2018, 71, 409-413.	1.9	7
207	Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry. European Heart Journal, 2018, 39, 687-695.	2.2	269
208	Predicting the unpredictable mortality outcome of valveâ€inâ€valve interventions. Catheterization and Cardiovascular Interventions, 2018, 92, 1171-1172.	1.7	0
209	Unmet Needs and Therapeutic Strategies in Cardio-Hemato-Oncology. Acta Haematologica, 2018, 140, 226-230.	1.4	4
210	Safety outcomes of new versus old generation transcatheter aortic valves. Catheterization and Cardiovascular Interventions, 2018, 94, E44-E53.	1.7	13
211	Clinical Valve Thrombosis After Transcatheter Aortic Valve-in-Valve Implantation. Circulation: Cardiovascular Interventions, 2018, 11, e006730.	3.9	51
212	Periprocedural myocardial infarction in chronic total occlusion: The challenge of precise diagnosis and prognostication. Catheterization and Cardiovascular Interventions, 2018, 92, 486-487.	1.7	4
213	Prodromal symptoms predict myocardial involvement in patients with acute idiopathic pericarditis. International Journal of Cardiology, 2018, 270, 197-199.	1.7	11
214	latrogenic atrial septal defect post mitral valve in valve implantation. Cardiovascular Revascularization Medicine, 2018, 19, 82-85.	0.8	4
215	The double jeopardy of aortic stenosis in cancer patients. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 150-151.	4.0	1

Impact of Self-Reported Family History of Premature Cardiovascular Disease on the Outcomes of Patients Hospitalized for Acute Coronary Syndrome (from the Acute Coronary Syndrome Israel Survey) Tj ETQq0 0 **0.6**gBT /Oværlock 10 T 216

#	Article	IF	CITATIONS
217	Relation of Left Ventricular Fractional Shortening to Needfor Permanent Pacemaker After Transcatheter AorticValve Implantation. American Journal of Cardiology, 2018, 122, 833-837.	1.6	3
218	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. European Heart Journal, 2018, 39, 3314-3321.	2.2	116
219	The effect of cessation of 2nd generation P2Y12 inhibitor therapy on platelet reactivity in patients 1 year after acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2018, 46, 351-358.	2.1	Ο
220	Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. EuroIntervention, 2018, 14, e343-e351.	3.2	21
221	Exploring Tricuspid Regurgitation in Treating Degenerated Bioprosthetic Aortic Valves. JACC: Cardiovascular Interventions, 2018, 11, 1161-1163.	2.9	Ο
222	Online Angiography Image-Based FFR Assessment During Coronary Catheterization: A Single-Center Study. Journal of Invasive Cardiology, 2018, 30, 224-229.	0.4	6
223	Yield of left ventricular dyssynchrony by gated SPECT MPI in patients with heart failure prior to implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator: Characteristics and prediction of cardiac outcome. Journal of Nuclear Cardiology, 2017, 24, 122-129.	2.1	17
224	Sex differences in aortic root and vascular anatomy in patients undergoing transcatheter aortic valve implantation: A computed-tomographic study. Journal of Cardiovascular Computed Tomography, 2017, 11, 87-96.	1.3	23
225	Balloon dilatation and outcome among patients undergoing trans-femoral aortic valve replacement. International Journal of Cardiology, 2017, 230, 537-541.	1.7	10
226	Effect of transcatheter aortic valve size and position on valve-in-valve hemodynamics: An inÂvitro study. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 1303-1315.e1.	0.8	50
227	Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	28
228	Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses. JACC: Cardiovascular Interventions, 2017, 10, 1048-1056.	2.9	117
229	Prognostic significance of aortic valve gradient in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2017, 90, 1175-1182.	1.7	5
230	The gut microbiome and cardiovascular risk: current perspective and gaps of knowledge. Future Cardiology, 2017, 13, 191-194.	1.2	9
231	The problem of delirium following transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2017, 89, 1292-1293.	1.7	1
232	BIOFLOW-III satellite—One-year clinical outcomes of diabetic patients treated with a biodegradable polymer sirolimus-eluting stent and comprehensive medical surveillance. Cardiovascular Revascularization Medicine, 2017, 18, 338-343.	0.8	3
233	Long-Term Outcomes of 560 Consecutive Patients Treated With Transcatheter Aortic Valve Implantation and Propensity Score–Matched Analysis of Early- Versus New-Generation Valves. American Journal of Cardiology, 2017, 119, 1821-1831.	1.6	17
234	Transcatheter Aortic Valve Implantation Futility Risk Model Development and Validation Among Treated Patients With Aortic Stenosis. American Journal of Cardiology, 2017, 120, 2241-2246.	1.6	15

#	Article	IF	CITATIONS
235	Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. American Journal of Cardiology, 2017, 120, 2025-2030.	1.6	18
236	Transcatheter Valve Implantation in Degenerated Bioprosthetic Surgical Valves (ViV) in Aortic, Mitral, and Tricuspid Positions: A Review. Structural Heart, 2017, 1, 225-235.	0.6	4
237	Validation Study of Image-Based Fractional Flow Reserve During Coronary Angiography. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	82
238	Comparison of Outcome of Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis in 3 Age Groups (≤0; 71 to 80, and ≥81 Years). American Journal of Cardiology, 2017, 120, 1607-1611.	1.6	11
239	The Prognostic Effects of Coronary Disease Severity and Completeness of Revascularization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2017, 10, 1428-1435.	2.9	90
240	The double jeopardy of percutaneous coronary interventions in patients with previous stroke. Coronary Artery Disease, 2017, 28, 539-540.	0.7	3
241	Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. Circulation, 2017, 136, 1304-1314.	1.6	43
242	Characterization of surface antigens of reticulated immature platelets. Journal of Thrombosis and Thrombolysis, 2017, 44, 291-297.	2.1	22
243	Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With STâ€Elevation Myocardial Infarction: Results From a Multiâ€Center Randomized Trial. Journal of the American Heart Association, 2017, 6, .	3.7	10
244	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. Journal of the American College of Cardiology, 2017, 70, 60-74.	2.8	51
245	Temporal trends in transcatheter aortic valve implantation, 2008–2014: patient characteristics, procedural issues, and clinical outcome. Clinical Cardiology, 2017, 40, 82-88.	1.8	29
246	Is Transcatheter Aortic Valve Replacement Taking the Path of Disruptive Innovation Technology?. Structural Heart, 2017, 1, 138-142.	0.6	2
247	Transcatheter Aortic Valve Replacement in Female Patients—Present Scenario. Indian Journal of Cardiovascular Disease in Women WINCARS, 2017, 02, 007-013.	0.1	0
248	Case Report of First Angiography-Based On-Line FFR Assessment during Coronary Catheterization. Case Reports in Cardiology, 2017, 2017, 1-4.	0.2	2
249	Effect of vitamin D on endothelial progenitor cells function. PLoS ONE, 2017, 12, e0178057.	2.5	27
250	Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure. Cardiovascular Diabetology, 2017, 16, 102.	6.8	22
251	Evaluating TAVI outcomes—not just a matter of life and death. Annals of Translational Medicine, 2017, 5, 84-84.	1.7	1
252	Comparative Matched Outcome of Evolut-R vs CoreValve Transcatheter Aortic Valve Implantation. Journal of Invasive Cardiology, 2017, 29, 69-74.	0.4	13

#	Article	IF	CITATIONS
253	Long Term Outcomes of MGuard Stent Deployment in Saphenous Vein Grafts and Native Coronary Arteries: A Single Center Experience. Israel Medical Association Journal, 2017, 19, 172-176.	0.1	4
254	Coronary Artery Calcium Score: Where Do We Stand? Current Uses and Implications in Asymptomatic Patients. Israel Medical Association Journal, 2017, 19, 214-215.	0.1	1
255	Incremental Value of Transesophageal Echocardiography Integrated with Transthoracic Echocardiography in the Assessment of Aortic Stenosis Severity. Journal of Heart Valve Disease, 2017, 26, 509-517.	0.5	2
256	Transcatheter Mitral Valve Replacement inÂNativeÂMitral Valve Disease With SevereÂMitralÂAnnular Calcification. JACC: Cardiovascular Interventions, 2016, 9, 1361-1371.	2.9	257
257	Bifurcation stenting with bioresorbable scaffolds: Quo vadis?. Catheterization and Cardiovascular Interventions, 2016, 88, 863-864.	1.7	Ο
258	Urgent Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Acute Heart Failure: Procedural and 30-Day Outcomes. Canadian Journal of Cardiology, 2016, 32, 726-731.	1.7	41
259	Impact of Renal Dysfunction on Results of Transcatheter Aortic Valve Replacement Outcomes in a Large Multicenter Cohort. American Journal of Cardiology, 2016, 118, 1888-1896.	1.6	37
260	One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). American Journal of Cardiology, 2016, 118, 1111-1116.	1.6	2
261	The 3 S's of the Sapien balloon expandable valve. Catheterization and Cardiovascular Interventions, 2016, 88, 476-478.	1.7	1
262	Fractional Flow Reserve Derived From Routine Coronary Angiograms. Journal of the American College of Cardiology, 2016, 68, 2235-2237.	2.8	36
263	The alternative approach to transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2016, 87, 339-340.	1.7	2
264	Acute Gain in Minimal Lumen AreaÂFollowing Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds orÂXience Metallic Stents. JACC: Cardiovascular Interventions, 2016, 9, 1216-1227.	2.9	18
265	Transcatheter Replacement of Failed Bioprosthetic Valves. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	104
266	Mortality prediction following transcatheter aortic valve replacement: A quantitative comparison of risk scores derived from populations treated with either surgical or percutaneous aortic valve replacement. The Israeli TAVR Registry Risk Model Accuracy Assessment (IRRMA) study. International Journal of Cardiology, 2016, 215, 227-231.	1.7	36
267	Platelet reactivity in patients undergoing transcatheter aortic valve implantation. Journal of Thrombosis and Thrombolysis, 2016, 42, 11-18.	2.1	18
268	Type of Atrial Fibrillation and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. Annals of Noninvasive Electrocardiology, 2016, 21, 519-525.	1.1	9
269	Type 2 myocardial infarction: A descriptive analysis and comparison with type 1 myocardial infarction. Journal of Cardiology, 2016, 67, 51-56.	1.9	39
270	Outcome of contemporary acute coronary syndrome complicated by ventricular tachyarrhythmias. Europace, 2016, 18, 219-226.	1.7	27

#	Article	IF	CITATIONS
271	Usefulness of the CHA2DS2-VASC Score to Predict Adverse Outcomes in Patients Having Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 117, 1433-1438.	1.6	30
272	Relation of Adiponectin to All-Cause Mortality, Cardiovascular Mortality, and Major Adverse Cardiovascular Events (from the Dallas Heart Study). American Journal of Cardiology, 2016, 117, 574-579.	1.6	35
273	Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. Leukemia Research, 2016, 41, 56-61.	0.8	7
274	The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease. American Journal of Cardiology, 2016, 117, 477-482.	1.6	17
275	Contemporary issues related to STEMI management. Minerva Cardioangiologica, 2016, 64, 217-8.	1.2	0
276	Insights from 2D and 3D Quantitative Angiographic Assessment of Bioresorbable Everolimus-Eluting Vascular Scaffolds. Israel Medical Association Journal, 2016, 18, 318-385.	0.1	2
277	Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome. Israel Medical Association Journal, 2016, 18, 433-434.	0.1	5
278	A secondâ€ŧime percutaneous aorticâ€valve implantation for bioprosthetic failure. Clinical Case Reports (discontinued), 2015, 3, 753-756.	0.5	0
279	Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardio-Oncology, 2015, 1, 5.	1.7	38
280	Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardio-Oncology, 2015, 1, 6.	1.7	25
281	Transcatheter aortic valve implantation for bicuspid aortic valve stenosis. Catheterization and Cardiovascular Interventions, 2015, 86, 331-333.	1.7	3
282	Editorial comment Non-culprit lesion percutaneous coronary intervention during acute myocardial infarction – the road not taken?. Postepy W Kardiologii Interwencyjnej, 2015, 2, 71-73.	0.2	0
283	Prognosis of STEMI Patients with Multi-Vessel Disease Undergoing Culprit-Only PCI without Significant Residual Ischemia on Non-Invasive Stress Testing. PLoS ONE, 2015, 10, e0138474.	2.5	8
284	Long-Lived αMUPA Mice Show Attenuation of Cardiac Aging and Leptin-Dependent Cardioprotection. PLoS ONE, 2015, 10, e0144593.	2.5	11
285	Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 1966-1974.	2.9	49
286	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment– Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	4
287	Coronary Obstruction in Transcatheter Aortic Valve-in-Valve Implantation. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	202
288	Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, e001484.	3.9	15

#	Article	IF	CITATIONS
289	Predictors of Long Term Outcomes in 11,441 Consecutive Patients Following Percutaneous Coronary Interventions. American Journal of Cardiology, 2015, 115, 855-859.	1.6	24
290	Long-Term Outcomes for Patients With Severe Symptomatic Aortic Stenosis Treated With Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2015, 116, 1391-1398.	1.6	33
291	Optimal Duration of Dual Antiplatelet Therapy After Coronary Stent Implantation. American Journal of Cardiology, 2015, 116, 1631-1636.	1.6	1
292	Outcomes of Patients at Estimated Low, Intermediate, and High Risk Undergoing Transcatheter Aortic Valve Implantation for Aortic Stenosis. American Journal of Cardiology, 2015, 116, 1916-1922.	1.6	43
293	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. Circulation: Cardiovascular Interventions, 2015, 8, e002475.	3.9	148
294	Can cardio-oncology deliver better care internationally?. Future Oncology, 2015, 11, 2259-2262.	2.4	1
295	The incremental impact of residual <scp>SYNTAX</scp> score on longâ€ŧerm clinical outcomes in patients with multivessel coronary artery disease treated by percutaneous coronary interventions. Catheterization and Cardiovascular Interventions, 2015, 86, 3-10.	1.7	19
296	Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes. European Journal of Preventive Cardiology, 2014, 21, 1153-1162.	1.8	16
297	Transcatheter Aortic Valve Replacement inÂBicuspid Aortic Valve Disease. Journal of the American College of Cardiology, 2014, 64, 2330-2339.	2.8	280
298	Transcatheter Aortic Valve Implantation in Failed Bioprosthetic Surgical Valves. JAMA - Journal of the American Medical Association, 2014, 312, 162.	7.4	762
299	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	2.2	275
300	Aspiration Thrombectomy in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Acute Coronary Syndrome Israeli Survey 2010). American Journal of Cardiology, 2014, 113, 809-814.	1.6	4
301	Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the) Tj ETQq1 1 0. American Journal of Cardiology, 2014, 114, 9-16.	784314 rg 1.6	gBT /Overlock 38
302	Percutaneous coronary intervention of the left main artery before MitraClip implantation. Cardiovascular Revascularization Medicine, 2014, 15, 51-53.	0.8	1
303	Response to Prasugrel and Levels of Circulating Reticulated Platelets in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 513-517.	2.8	80
304	Gender Differences in Left Ventricular Function Following Percutaneous Coronary Intervention for First Anterior Wall ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 114, 1473-1478.	1.6	8
305	Meta-Analysis of Predictors of All-Cause Mortality After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2014, 114, 1447-1455.	1.6	82
306	A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary) Tj ETQq0 0 0 r	gBT /Over	ock 10 Tf 50

2014, 35, 2021-2031.

#	Article	IF	CITATIONS
307	Comparison of Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Discharged on Versus Not on Statin Therapy (from the Harmonizing Outcomes With Revascularization and Stents in) Tj ETQq1 1	. 0.7 84314	1 ∎g BT /Ove
308	Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thrombosis Research, 2014, 134, 121-124.	1.7	9
309	Impact of Multiple Complex Plaques on Short- and Long-Term Clinical Outcomes in Patients Presenting With ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With) Tj ETQq1 1 0.784314 r	gBT /Overl 1.6	lock 10 Tf
310	of Cardiology, 2014, 113, 1621-1627. The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: A substudy of the COMFORTABLE AMI trial. International Journal of Cardiology, 2014, 175, 314-322.	1.7	24
311	Câ€THV measures of selfâ€expandable valve positioning and correlation with implant outcomes. Catheterization and Cardiovascular Interventions, 2014, 84, 877-884.	1.7	2
312	Heme Oxygenase-1 Induction Improves Cardiac Function following Myocardial Ischemia by Reducing Oxidative Stress. PLoS ONE, 2014, 9, e92246.	2.5	64
313	MGuard Embolic Protection Stent – The Importance of Thrombus Management in ST-elevation Myocardial Infarction Primary Percutaneous Coronary Intervention. Interventional Cardiology Review, 2014, 9, 168.	1.6	0
314	Long-term comparative analysis from an all-comer cohort of coronary patients treated using first- and second-generation drug-eluting stents. Journal of Invasive Cardiology, 2014, 26, 378-84.	0.4	3
315	Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction With Versus Without Previous Coronary Artery Bypass Grafting (from the Harmonizing Outcomes With) Tj ETQq1 1 0.784314 of Cardiology, 2013, 111, 1377-1386.	rgBT /Ove	rloçk 10 Tf
316	Transcatheter aortic valve implantation of a CoreValve device using novel real-time imaging guidance. Cardiovascular Revascularization Medicine, 2013, 14, 49-52.	0.8	6
317	Clinical profile and outcome of patients with severe aortic stenosis at high surgical risk: Singleâ€center prospective evaluation according to treatment assignment. Catheterization and Cardiovascular Interventions, 2013, 81, 871-881.	1.7	13
318	Therapeutic Angiogenesis Revisited. Catheterization and Cardiovascular Interventions, 2013, 82, 907-908.	1.7	1
319	Multicenter Evaluation of Edwards SAPIEN Positioning During Transcatheter Aortic Valve Implantation With Correlates for Device Movement During Final Deployment. JACC: Cardiovascular Interventions, 2012, 5, 563-570.	2.9	38
320	Transcatheter aortic valveâ€inâ€valve implantation for procedural related aortic regurgitation. Catheterization and Cardiovascular Interventions, 2012, 80, 148-150.	1.7	0
321	Multivessel Versus Culprit-Only Revascularization: One Time Versus Staged Procedures for the ACS Population. Current Cardiology Reports, 2012, 14, 528-536.	2.9	5
322	Leftâ€ventricular outflow tract ventricularâ€tachycardia event following corevalve transcatheter aorticâ€valve implantation. Catheterization and Cardiovascular Interventions, 2012, 79, 331-333.	1.7	8
323	A comparative analysis of major clinical outcomes with drug-eluting stents versus bare metal stents in male versus female patients. EuroIntervention, 2012, 7, 1051-1059.	3.2	25
324	Insufficient HO1 Response to Ischemic Stress Correlates with Increased Inflammation and Reduced Survival of EPCs in Diabetic Patients. FASEB Journal, 2012, 26, 1114.11.	0.5	0

#	Article	IF	CITATIONS
325	Prognostic Impact of Staged Versus "One-Time―Multivessel Percutaneous Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 704-711.	2.8	236
326	A comparative analysis of major clinical outcomes using drugâ€eluting stents versus bare metal stents in diabetic versus nondiabetic patients. Catheterization and Cardiovascular Interventions, 2011, 78, 710-717.	1.7	16
327	The ACSIS Registry and primary angioplasty following coronary bypass surgery. Catheterization and Cardiovascular Interventions, 2011, 78, 537-539.	1.7	21
328	Failure of drug eluting stents presented as definite stent thrombosis. Catheterization and Cardiovascular Interventions, 2010, 76, 93-97.	1.7	1
329	Percutaneous aortic valve implantation using novel imaging guidance. Catheterization and Cardiovascular Interventions, 2010, 76, 450-454.	1.7	27
330	The MGuard stent: Current promises and limitations. Catheterization and Cardiovascular Interventions, 2010, 75, 642-643.	1.7	3
331	Refractory myocardial angina and determinants of prognosis. Catheterization and Cardiovascular Interventions, 2010, 75, 892-894.	1.7	6
332	The titanium nitride oxide coated stent. Catheterization and Cardiovascular Interventions, 2010, 76, 288-290.	1.7	2
333	Gender medicine and drug eluting coronary stents. Catheterization and Cardiovascular Interventions, 2010, 76, 814-816.	1.7	0
334	A critical appraisal of the Janus carbostent. Catheterization and Cardiovascular Interventions, 2009, 73, 249-250.	1.7	4
335	The challenges of stem cell treatment in ischemic heart disease. Catheterization and Cardiovascular Interventions, 2009, 73, 289-290.	1.7	0
336	The need for a dedicated bifurcation stenting system. Catheterization and Cardiovascular Interventions, 2009, 73, 641-642.	1.7	3
337	Preliminary experiences using the MGuard stent platform in saphenous vein graft lesions. Catheterization and Cardiovascular Interventions, 2009, 74, 1055-1057.	1.7	15
338	The "mini rush―technique for managing bifurcation lesions. Catheterization and Cardiovascular Interventions, 2009, 74, 85-87.	1.7	0
339	The risk of cardiac complications following noncardiac surgery in patients with drug eluting stents implanted at least six months before surgery. Catheterization and Cardiovascular Interventions, 2009, 74, 837-843.	1.7	32
340	A thriller with a happy end. Catheterization and Cardiovascular Interventions, 2009, 74, 808-810.	1.7	0
341	PRO-Kinetic: results from an "all-comers―single centre clinical experience. EuroIntervention, 2009, 5, 109-114.	3.2	18
342	Percutaneous coronary intervention for chronic total occlusion: Novel 3â€dimensional imaging and quantitative analysis. Catheterization and Cardiovascular Interventions, 2008, 71, 784-789.	1.7	14

#	Article	IF	CITATIONS
343	Drugâ€eluting stent in saphenous vein graft lesions. Catheterization and Cardiovascular Interventions, 2008, 71, 894-895.	1.7	4
344	Drugâ€eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. Catheterization and Cardiovascular Interventions, 2008, 72, 33-35.	1.7	0
345	Transcatheter aortic valveâ€inâ€valve implant. Catheterization and Cardiovascular Interventions, 2008, 72, 149-150.	1.7	0
346	Results of the U.S. ARRIVE 1 registry: 2â€year outcomes. Catheterization and Cardiovascular Interventions, 2008, 72, 446-447.	1.7	1
347	Completeness of revascularization in patients with STâ€Elevation acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2008, 72, 934-936.	1.7	9
348	Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: Insights from the NIRTOP study. Acute Cardiac Care, 2008, 10, 104-110.	0.2	14
349	Angiographic findings and clinical outcomes in asymptomatic patients with severe obstructive atherosclerosis on computed tomography angiography. Israel Medical Association Journal, 2008, 10, 627-33.	0.1	5
350	The impact of renal insufficiency on patients outcomes in emergent angioplasty for acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2007, 69, 395-400.	1.7	27
351	Imaging of vulnerable coronary artery plaques. Catheterization and Cardiovascular Interventions, 2007, 70, 66-75.	1.7	32
352	The LightWire technology for catheter-based interventions. Catheterization and Cardiovascular Interventions, 2007, 70, 543-551.	1.7	1
353	Results of percutaneous coronary interventions in patients ≥90 years of age. Catheterization and Cardiovascular Interventions, 2007, 70, 937-943.	1.7	27
354	The impact of circadian variation on outcomes in emergency acute anterior myocardial infarction percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2006, 67, 221-226.	1.7	41
355	Drug-eluting stents in bifurcation lesions: To stent one branch or both?. Catheterization and Cardiovascular Interventions, 2006, 68, 891-896.	1.7	38
356	Characteristics and clinical outcomes of patients with cardiogenic shock complicating acute myocardial infarction treated by emergent coronary angioplasty. International Journal of Cardiovascular Interventions, 2005, 7, 193-198.	0.5	6
357	The ACIST power injection system reduces the amount of contrast media delivered to the patient, as well as fluoroscopy time, during diagnostic and interventional cardiac procedures. International Journal of Cardiovascular Interventions, 2005, 7, 183-187.	0.5	22
358	Refractory myocardial ischemic syndromes: patients' characterization and treatment goals. Future Cardiology, 2005, 1, 629-635.	1.2	3
359	The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction. International Journal of Cardiovascular Interventions, 2005, 7, 41-45.	0.5	6
360	Threeâ€dimensional coronary reconstruction from routine singleâ€plane coronary angiograms: in vivo quantitative validation. International Journal of Cardiovascular Interventions, 2005, 7, 141-145.	0.5	39

#	Article	IF	CITATIONS
361	Acute and intermediateâ€ŧerm procedural results using cypher stenting to treat multiâ€vessel coronary artery disease. International Journal of Cardiovascular Interventions, 2005, 7, 122-125.	0.5	1
362	Clinical experiences using the FilterWire EX for distal embolic protection during complex percutaneous coronary interventions. International Journal of Cardiovascular Interventions, 2004, 6, 28-32.	0.5	5
363	Acute and intermediateâ€ŧerm clinical outcomes following Heparin coated BX coronary stent implantation in patients with thrombus containing lesions. International Journal of Cardiovascular Interventions, 2004, 6, 77-81.	0.5	1
364	Autologous stem cells for functional myocardial repair. Heart Failure Reviews, 2003, 8, 237-245.	3.9	9
365	Preliminary experiences using X-sizer catheter for mechanical thrombectomy of thrombus-containing lesions during acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2003, 58, 443-448.	1.7	15
366	Use of filterwire EX for distal embolic protection during complex percutaneous coronary interventions: Four case studies. Catheterization and Cardiovascular Interventions, 2003, 58, 364-369.	1.7	4
367	Acute and intermediateâ€ŧerm results of percutaneous coronary stenting in octogenarian patients. International Journal of Cardiovascular Interventions, 2003, 5, 195-199.	0.5	13
368	Validation of vital signs recorded via a new telecare system. Journal of Telemedicine and Telecare, 2003, 9, 328-333.	2.7	5
369	Collateral formation and clinical variables in obstructive coronary artery disease: the influence of hypercholesterolemia and diabetes mellitus. Coronary Artery Disease, 2003, 14, 61-64.	0.7	44
370	Safety and efficacy of a 6 French perclose arterial suturing device following percutaneous coronary interventions: a pilot evaluation. Journal of Invasive Cardiology, 2002, 14, 741-5.	0.4	16
371	Lowâ€power helium: Neon laser irradiation enhances production of vascular endothelial growth factor and promotes growth of endothelial cells in vitro. Lasers in Surgery and Medicine, 2001, 28, 355-364.	2.1	196
372	Catheter-based electromechanical mapping to assess regional myocardial function: A comparative analysis with transthoracic echocardiography. Catheterization and Cardiovascular Interventions, 2001, 52, 342-347.	1.7	10
373	Assessment of NOGA catheter stability during the entire cardiac cycle by means of a special needle-tipped catheter. Catheterization and Cardiovascular Interventions, 2001, 52, 400-406.	1.7	10
374	Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. Catheterization and Cardiovascular Interventions, 2001, 54, 295-300.	1.7	25
375	Global improvement in left ventricular performance observed with cardiac contractility modulation is the result of changes in regional contractility. Heart Failure Reviews, 2001, 6, 35-44.	3.9	4
376	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. Circulation, 2001, 104, 642-647.	1.6	207
377	Angiogenesis Therapy. Circulation, 2001, 104, 115-119.	1.6	237
378	Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease. Catheterization and Cardiovascular Interventions, 2000, 50, 245-254.	1.7	18

#	Article	IF	CITATIONS
379	Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. Catheterization and Cardiovascular Interventions, 2000, 51, 131-137.	1.7	7
380	Delivery Strategies to Achieve Therapeutic Myocardial Angiogenesis. Circulation, 2000, 101, 454-458.	1.6	124
381	Catheter-based transendocardial gene delivery for therapeutic myocardial angiogenesis. International Journal of Cardiovascular Interventions, 2000, 3, 67-70.	0.5	6
382	Left Ventricular Electromechanical Mapping of Myocardial Ischemia. Circulation, 1999, 99, 2708-2708.	1.6	3
383	Percutaneous Transmyocardial Laser Revascularization: An Overview. Catheterization and Cardiovascular Interventions, 1999, 47, 354-359.	1.7	22
384	Left ventricular electromechanical mapping: Current understanding and diagnostic potential. Catheterization and Cardiovascular Interventions, 1999, 48, 421-429.	1.7	11
385	Evaluation of the acute and chronic safety of the biosense injection catheter system in porcine hearts. Catheterization and Cardiovascular Interventions, 1999, 48, 447-453.	1.7	45
386	Images in Cardiovascular Interventions Optimizing stent expansion and apposition using intravascular ultrasound. International Journal of Cardiovascular Interventions, 1999, 2, 195-195.	0.5	0
387	Detection of myocardial viability in the catheterization laboratory using the Biosense-guided electromechanical mapping system. International Journal of Cardiovascular Interventions, 1999, 2, 125-128.	0.5	5
388	Intravascular ultrasound observations of atherosclerotic lesion formation and restenosis in patients with diabetes mellitus. International Journal of Cardiovascular Interventions, 1999, 2, 13-20.	0.5	11
389	Angiographic Morphology Following Heparin and Aspirin Therapy in Patients with Acute Coronary Syndromes and Intracoronary Thrombus. Journal of Thrombosis and Thrombolysis, 1998, 5, 159-164.	2.1	1
390	Comparison Between Left Ventricular Electromechanical Mapping and Radionuclide Perfusion Imaging for Detection of Myocardial Viability. Circulation, 1998, 98, 1837-1841.	1.6	98
391	Preliminary Animal and Clinical Experiences Using an Electromechanical Endocardial Mapping Procedure to Distinguish Infarcted From Healthy Myocardium. Circulation, 1998, 98, 1116-1124.	1.6	166
392	Procedural Results and Late Clinical Outcomes After Placement of Three or More Stents in Single Coronary Lesions. Circulation, 1998, 97, 1355-1361.	1.6	61
393	Delayed development of a pseudoaneurysm in the left circumflex artery following angioplasty and stent placement, treated with intravascular ultrasound-guided stenting. , 1997, 42, 51-53.		19
394	Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. Cardiovascular Drugs and Therapy, 1996, 10, 75-79.	2.6	5
395	Prognostic importance of previous myocardial infarction in patients receiving thrombolytic therapy for acute infarction. Journal of Thrombosis and Thrombolysis, 1996, 3, 391-395.	2.1	2
396	Endothelin and myocardial ischemia. Cardiovascular Drugs and Therapy, 1994, 8, 589-599.	2.6	44

#	Article	IF	CITATIONS
397	Temporal Trends in Complex Percutaneous Coronary Interventions. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	7